BR112016015712A8 - method of treatment of liver disease. - Google Patents

method of treatment of liver disease. Download PDF

Info

Publication number
BR112016015712A8
BR112016015712A8 BR112016015712A BR112016015712A BR112016015712A8 BR 112016015712 A8 BR112016015712 A8 BR 112016015712A8 BR 112016015712 A BR112016015712 A BR 112016015712A BR 112016015712 A BR112016015712 A BR 112016015712A BR 112016015712 A8 BR112016015712 A8 BR 112016015712A8
Authority
BR
Brazil
Prior art keywords
treatment
liver disease
liver
disease
Prior art date
Application number
BR112016015712A
Other languages
Portuguese (pt)
Other versions
BR112016015712A2 (en
Inventor
Matsuda Kazuko
Original Assignee
Medicinova Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medicinova Inc filed Critical Medicinova Inc
Publication of BR112016015712A2 publication Critical patent/BR112016015712A2/en
Publication of BR112016015712A8 publication Critical patent/BR112016015712A8/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BR112016015712A 2014-01-10 2015-01-07 method of treatment of liver disease. BR112016015712A8 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14/152,924 US8962687B2 (en) 2012-12-05 2014-01-10 Method of treating liver disorders
PCT/US2015/010479 WO2015105874A1 (en) 2014-01-10 2015-01-07 Method of treating liver disorders

Publications (2)

Publication Number Publication Date
BR112016015712A2 BR112016015712A2 (en) 2017-08-08
BR112016015712A8 true BR112016015712A8 (en) 2018-04-17

Family

ID=50826043

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016015712A BR112016015712A8 (en) 2014-01-10 2015-01-07 method of treatment of liver disease.

Country Status (10)

Country Link
US (2) US8962687B2 (en)
EP (1) EP3091972B1 (en)
JP (2) JP2017502056A (en)
KR (1) KR102352729B1 (en)
CN (1) CN105934243A (en)
BR (1) BR112016015712A8 (en)
CA (1) CA2935933C (en)
ES (1) ES2917982T3 (en)
TW (1) TW201609081A (en)
WO (1) WO2015105874A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016028196A2 (en) * 2014-06-02 2018-06-26 Medicinova Inc fibrosis inhibition or treatment method
WO2016085994A1 (en) * 2014-11-26 2016-06-02 Medicinova, Inc. Ibudilast and telmisartan for treating non-alcoholic fatty liver disease, non alcoholic steatohepatitis, and advanced non alcoholic steatohepatitis
US10588880B2 (en) 2016-09-28 2020-03-17 Eiger Biopharmaceuticals, Inc. Methods and pharmaceutical compositions for the treatment of non-alcoholic steatohepatitis
WO2019106851A1 (en) * 2017-11-30 2019-06-06 株式会社メディコ・コンスル Combination drug suitable for treatment and prevention of non-alcoholic fatty liver disease (naflad) and/or non-alcoholic steatohepatitis (nash), and/or hepatic steatosis
CN117320701A (en) * 2021-05-28 2023-12-29 美迪诺亚公司 Method for reducing synthesis of triglyceride in liver

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2585246A1 (en) 1985-07-26 1987-01-30 Cortial PROCESS FOR OBTAINING SOLID PHARMACEUTICAL FORMS WITH PROLONGED RELEASE
US4788055A (en) 1985-12-09 1988-11-29 Ciba-Geigy Corporation Resinate sustained release dextromethorphan composition
GB8613688D0 (en) 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
GB8613689D0 (en) 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
US4816264A (en) 1986-06-06 1989-03-28 Warner-Lambert Company Sustained release formulations
FI76778C (en) 1986-09-22 1988-12-12 Kyro Oy FOERFARANDE OCH ANORDNING FOER TRANSPORT AV GLASSKIVOR UNDER UPPHETTNING OCH HAERDNING.
US4985585A (en) 1988-03-07 1991-01-15 Kyorin Pharmaceutical Co., Ltd. Phenoxyalkylcarboxylic acid derivatives and process for their preparations
US4996047A (en) 1988-11-02 1991-02-26 Richardson-Vicks, Inc. Sustained release drug-resin complexes
CA2002492A1 (en) 1988-11-11 1990-05-11 Sandra T. A. Malkowska Pharmaceutical ion exchange resin composition
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5290812A (en) 1991-01-18 1994-03-01 Kyorin Pharmaceutical Co., Ltd. Phenoxyalkylcarboxylic acid derivatives and process of preparing the same
US7060854B2 (en) 2003-06-24 2006-06-13 Medicinova, Inc. Process for making polymorphic form A of 4-[6-acetyl-3-[3-(4-acetyl-3-hydroxy-2-propylphenylthio)propoxy]-2-propylphenoxy]butyric acid
US7064146B2 (en) 2003-06-24 2006-06-20 Medicinova, Inc. Pharmaceutical compositions of isolated orthorhombic crystalline 4-[6-acetyl-3-[3-(4-acetyl-3-hydroxy-2-propylphenylthio)propoxy]-2-propylphenoxy]butyric acid and methods of use
US8835499B2 (en) 2011-12-08 2014-09-16 Medicinova, Inc. Method of treating non-alcoholic fatty liver disease and steatohepatitis

Also Published As

Publication number Publication date
WO2015105874A1 (en) 2015-07-16
CN105934243A (en) 2016-09-07
TW201609081A (en) 2016-03-16
CA2935933A1 (en) 2015-07-16
JP2017502056A (en) 2017-01-19
EP3091972A1 (en) 2016-11-16
EP3091972B1 (en) 2022-06-01
JP2019218379A (en) 2019-12-26
KR102352729B1 (en) 2022-01-18
ES2917982T3 (en) 2022-07-12
BR112016015712A2 (en) 2017-08-08
KR20160099716A (en) 2016-08-22
EP3091972A4 (en) 2017-08-23
US8962687B2 (en) 2015-02-24
US20150209314A1 (en) 2015-07-30
CA2935933C (en) 2022-06-28
US20140155484A1 (en) 2014-06-05

Similar Documents

Publication Publication Date Title
SG11201701723XA (en) Methods of treating liver disease
DK3212233T3 (en) COMBINATION THERAPY FOR TREATMENT OF DISEASE
DK3235465T3 (en) IMPLANT
DK3234134T3 (en) TARGETED RNA EDITING
DK3594238T3 (en) Antibody compositions for tumor treatment
DK3851537T3 (en) TREATMENT OF HYPERBILIRUBINAMIA
BR112017007053A2 (en) neuroactive compounds and methods of using this compound.
DK3560954T3 (en) MODIFIED J-CHAIN
BR112017018413A2 (en) pancreatitis treatment
DK3240612T3 (en) PROCEDURES FOR THE TREATMENT OF RHINTH DISEASES
BR112016022976A2 (en) METHODS FOR THE TREATMENT OF HCV
MA39483A (en) TARGET THERAPEUTIC AGENTS
DK3341479T3 (en) LNA-G Process
DK3231444T3 (en) New treatment
DK3265087T3 (en) PROCEDURE FOR TRADIPITANT TREATMENT
DE102015102730B8 (en) Interconnects
DK3166473T3 (en) ophthalmoscopes
BR112016015712A2 (en) method of treatment of liver disease.
DK3302478T3 (en) PAC-1 COMBINATION TREATMENT
DK3200783T3 (en) TREATMENT OF ERYTROMELALGY
FR3024647B1 (en) TRANSAT OF PUERICULTURE
KR20180084983A (en) Uses of Pyrimido-Pyrimidazinone for the Treatment of Cancer
DK3182980T3 (en) TREATMENT OF GLYCOSYLING DEFICIENCY DISEASES
BR112016019469A2 (en) treatment of h.pylori infections using mtan inhibitors
GB201622116D0 (en) Treatment of liver disease

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]